Codex DNA manufactures and sells laboratory equipment, synthetic biology instruments, reagents and associated products and related services, to pharmaceutical and academic laboratories worldwide. Co. has developed and commercialized products that include BioXp systems, including its BioXp 3250 system, BioXp kits for generating an array of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. Co. provides workflow solutions for the following areas: synthetic DNA for antibody and protein engineering of biologic drugs; synthetic DNA for genome editing; and synthetic DNA for metabolic pathway engineering The DNAY average annual return since 2021 is shown above.
The Average Annual Return on the DNAY average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DNAY average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DNAY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|